SLC29A1 and myelodysplastic syndrome: The prolonged survival in patients with high hENT1 expression may result from a better response compared with patients with low hENT1. Therefore, besides the prognosis predicting system such as IPSS/IPSS-Revision (IPSS-R) [25]/WHO prognostic scoring system (WPSS) [26], hENT1 expression level could serve as a complementary prognosis predictor for higher-risk MDS patients treated with decitabine.